Bridgefront Capital’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Bridgefront Capital’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,689	Closed	-$322K	–	746
2026 Q1	$322K	Buy	+10,689	New	+$344K	0.08%	375
2024 Q2	–	Sell	-15,292	Closed	-$216K	–	657
2024 Q1	$216K	Sell	15,292 -391	-2%	-$4.93K	0.16%	298
2023 Q4	$164K	Buy	+15,683	New	+$146K	0.12%	313
2022 Q4	–	Sell	-30,179	Closed	-$244K	–	513
2022 Q3	$244K	Sell	30,179 -16,508	-35%	-$146K	0.25%	185
2022 Q2	$351K	Buy	+46,687	New	+$407K	0.39%	93
2021 Q4	–	Sell	-26,293	Closed	-$256K	–	445
2021 Q3	$256K	Buy	+26,293	New	+$246K	0.27%	179
2021 Q2	–	Sell	-25,947	Closed	-$299K	–	898
2021 Q1	$299K	Buy	+25,947	New	+$298K	0.09%	429

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Bridgefront Capital's TEVA Position: Q2 2026 in Review

Bridgefront Capital sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q2 2026, closing a stake of 10,689 shares — an estimated $322K sold.

Bridgefront Capital first reported a position in TEVA in Q1 2021 and held it in 7 quarters. The position peaked at $351K in Q2 2022. 676 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Bridgefront Capital reported no remaining Teva Pharmaceutical Industries Limited position as of Q2 2026 after selling out during the quarter.
Bridgefront Capital sold 10,689 Teva Pharmaceutical Industries Limited shares in Q2 2026, an estimated $322K.
Bridgefront Capital first reported a position in Teva Pharmaceutical Industries Limited in Q1 2021 and held it in 7 quarters.
Bridgefront Capital's Teva Pharmaceutical Industries Limited position peaked at $351K in Q2 2022.
676 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q2 2026.

Based on Bridgefront Capital's 13F filing for Q2 2026, filed 14 Aug 2026.